Digirad sets up imaging service with two acquisitions
Gamma camera maker Digirad is going into cardiology imaging service in a big way, with the purchase of two companies and creation of a new subsidiary.The company announced early this month that it had established Orion Imaging Systems as a wholly owned
Gamma camera maker Digirad is going into cardiology imaging service in a big way, with the purchase of two companies and creation of a new subsidiary.
The company announced early this month that it had established Orion Imaging Systems as a wholly owned subsidiary to provide services to cardiology imaging facilities across the U.S.
The new company initially consisted of Florida Cardiology and Nuclear Medicine Group, with more than 20 physicians' offices, but it quickly acquired Nuclear Imaging Systems (NIS) of Malvern, PA, the largest mobile cardiology imaging service provider in the U.S. The service performs more than 6000 nuclear cardiology imaging studies each year in Pennsylvania, New Jersey, Maryland, and North Carolina. NIS was incorporated into Orion.
Digirad's primary product, the 2020tc Imager, is a lightweight portable gamma camera. The 2020tc will be installed in the back of a van.
Privately owned Digirad announced in May that it had received $10 million in private equity financing (SCAN, 5/10/00). Notable investors are Columbia/HCA Healthcare, the largest hospital chain in the U.S., and Mitsui, Digirad's Japanese distributor.
Digirad is using the funds to increase its manufacturing capacity and expand its sales and marketing efforts. The company is headquartered in San Diego.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
